Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Oncternal Therapeutics, Inc.Financial_Report.xls
EX-31.1 - EX-31.1 - Oncternal Therapeutics, Inc.d305905dex311.htm
EX-32.2 - EX-32.2 - Oncternal Therapeutics, Inc.d305905dex322.htm
EX-31.2 - EX-31.2 - Oncternal Therapeutics, Inc.d305905dex312.htm
EX-32.1 - EX-32.1 - Oncternal Therapeutics, Inc.d305905dex321.htm
EX-10.61 - EX-10.61 - Oncternal Therapeutics, Inc.d305905dex1061.htm
EX-10.60 - EX-10.60 - Oncternal Therapeutics, Inc.d305905dex1060.htm
10-K - FORM 10-K - Oncternal Therapeutics, Inc.d305905d10k.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

 

  (1)

Registration Statement (Form S-8 No. 333-118882) pertaining to the GTx, Inc. Directors’ Deferred Compensation Plan,

 

  (2)

Registration Statement (Form S-8 No. 333-112576) pertaining to the GTx, Inc. 2004 Equity Incentive Plan, 2004 Non-Employee Directors’ Stock Option Plan, 2002 Stock Option Plan, 2001 Stock Option Plan, 2000 Stock Option Plan, and 1999 Stock Option Plan,

 

  (3)

Registration Statement (Form S-8 No. 333-136527) pertaining to the GTx, Inc. Amended and Restated 2004 Non-Employee Directors’ Stock Option Plan,

 

  (4)

Registration Statements (Form S-8 Nos. 333-149661 and 333-165507) pertaining to the GTx, Inc. 2004 Equity Incentive Plan and the Amended and Restated 2004 Non-Employee Directors’ Stock Option Plan, and

 

  (5)

Registration Statement (Form S-3 No. 333-174396) of GTx, Inc. and in the related Prospectus

of our reports dated March 2, 2012, with respect to the financial statements of GTx, Inc. and with respect to the effectiveness of internal control over financial reporting of GTx, Inc., included in this Annual Report (Form 10-K) of GTx, Inc. for the year ended December 31, 2011.

/s/ Ernst & Young LLP

Memphis, Tennessee

March 2, 2012